RE: RE: Money FlowI have a hard time envisioning the current management team taking this all the way through the IND process. I would feel alot more comfortable with this stock if knew they had intentions of tendering out the clinical trial design and management.
Last number I can recall from the Pharmaceutical Research and Manufacturers of America for Phase 1 to market, was somewhere in the neighborhood of 800 million. About 16% of Phase 1 drugs go on to market - and Gap is still more than a year away from starting Phase 1. There will be many, MANY, PP's along way.